| Drug General Information |
| Drug ID |
D03BHM
|
| Former ID |
DCL000603
|
| Drug Name |
R1507
|
| Indication |
Graves' ophthalmopathy [ICD10:H06.2]
|
Phase 2 |
[1]
|
|---|
| Company |
Roche
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Insulin-like growth factor I receptor |
Target Info |
Inhibitor |
[2],
[3]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
HIF-1 signaling pathway
|
|
FoxO signaling pathway
|
|
Oocyte meiosis
|
|
Endocytosis
|
|
PI3K-Akt signaling pathway
|
|
AMPK signaling pathway
|
|
Focal adhesion
|
|
Adherens junction
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Long-term depression
|
|
Ovarian steroidogenesis
|
|
Progesterone-mediated oocyte maturation
|
|
Pathways in cancer
|
|
Transcriptional misregulation in cancer
|
|
Proteoglycans in cancer
|
|
Glioma
|
|
Prostate cancer
|
|
Melanoma
|
|
PANTHER Pathway
|
Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade
|
|
Insulin/IGF pathway-protein kinase B signaling cascade
|
|
Pathway Interaction Database
|
Plasma membrane estrogen receptor signaling
|
|
SHP2 signaling
|
|
IGF1 pathway
|
|
Posttranslational regulation of adherens junction stability and dissassembly
|
|
Integrins in angiogenesis
|
|
Stabilization and expansion of the E-cadherin adherens junction
|
|
Reactome
|
IRS-related events triggered by IGF1R
|
|
SHC-related events triggered by IGF1R
|
|
WikiPathways
|
Senescence and Autophagy in Cancer
|
|
Insulin Signaling
|
|
Endochondral Ossification
|
|
Focal Adhesion
|
|
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
|
|
Apoptosis
|
|
Signaling Pathways in Glioblastoma
|
|
TSH signaling pathway
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015801) |
|---|
| REF 2 | National Cancer Institute. Dictionary of Cancer Terms. 2009. |
|---|
| REF 3 | Clinical pipeline report, company report or official report of Roche (2009). |
|---|
